In the last few years, therapies targeting this pathway, such as those involving a BRAF inhibitor (BRAFi), have greatly improved the clinical outcome of BRAFV600mut metastatic melanoma [3,4,5,6,7,8]. Here, BRAF is linked to metastatic melanoma.